The combination of VILDABRY M500 (Vildagliptin 50mg and Metformin 500mg) is a potent, dual-action oral medication designed to treat Type 2 Diabetes. This combination is particularly effective because it targets two distinct physiological defects: it improves the way the body secretes insulin and simultaneously reduces the body’s resistance to that insulin.
VILDABRY 50 ( Vildagliptin 50mg )is a potent, reversible, and highly selective DPP-4 inhibitor (Dipeptidyl Peptidase-4 inhibitor). It is an oral antihyperglycemic agent designed to improve glycemic control in patients with Type 2 Diabetes by enhancing the body’s natural response to meals. Unlike some other drugs in its class, Vildagliptin is unique because of its […]
TENELIKING 20 (Teneligliptin 20mg) is an oral antidiabetic medication belonging to the DPP-4 inhibitor (Dipeptidyl Peptidase-4 inhibitor) class, often referred to as “gliptins.” It is used to manage blood glucose levels in adults with Type 2 Diabetes Mellitus. Teneligliptin is often distinguished from other gliptins by its unique chemical structure and its ability to be […]
SITABRIGHT M 1000 (Sitagliptin 50 mg + Metformin 1000 mg ) is a potent fixed-dose combination (FDC) used to achieve intensive glycemic control in patients with Type 2 Diabetes Mellitus. This specific strength is often used as a “maintenance dose” for patients who require a high level of Metformin to overcome significant insulin resistance but […]
SITABRIGHT M 500 (Sitagliptin 50 mg + Metformin 500 mg) is a powerful fixed-dose combination (FDC) medication used to treat Type 2 Diabetes Mellitus. It combines two different classes of drugs—a DPP-4 inhibitor and a Biguanide—to target blood sugar control from multiple physiological directions. This combination is often prescribed when Metformin alone is no longer […]
SITABRIGHT 100 (Sitagliptin 100 mg ) is a potent, highly selective oral antidiabetic medication used to manage Type 2 Diabetes Mellitus. It is the standard full therapeutic dose for adults with normal kidney function and belongs to the class of drugs known as DPP-4 inhibitors (Dipeptidyl Peptidase-4 inhibitors). Commonly referred to as a “smart” diabetes […]
SITABRIGHT 50 (Sitagliptin 50 mg ) is a highly selective, oral antidiabetic medication used to manage Type 2 Diabetes Mellitus. It belongs to a class of drugs known as DPP-4 inhibitors (Dipeptidyl Peptidase-4 inhibitors), often nicknamed “Gliptins.” Unlike older medications that force the pancreas to work constantly, Sitagliptin is “glucose-dependent,” meaning it primarily works only […]
The combination of SALUPRIDE PM2(Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg) is a powerful triple-drug therapy (often referred to as a “triple FDC”). It is designed for patients with Type 2 Diabetes whose blood sugar remains uncontrolled despite dual therapy. This “triple attack” targets diabetes through three distinct physiological pathways: insulin secretion, insulin sensitivity in […]
The combination of SALUPRIDE PM1(Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg) is a “Triple Fixed-Dose Combination” (FDC) used to treat Type 2 Diabetes. This specific strength is often the starting dose for triple therapy, providing a broad-spectrum approach to blood sugar management by attacking the disease from three different physiological angles. By keeping the Glimepiride […]
SALUPRIDE M2 (Glimepiride 2mg and Metformin 500mg) is a moderate-strength fixed-dose combination (FDC) used to treat Type 2 Diabetes. This combination is typically prescribed when the initial “entry-level” dose (1mg/500mg) or Metformin monotherapy fails to bring blood glucose levels within the target range. At this level, the treatment shifts from a “starting phase” to a […]
Login